Utah Medical Products, Inc. (UTMD)
NASDAQ: UTMD · Real-Time Price · USD
61.02
-1.06 (-1.71%)
Dec 20, 2024, 4:00 PM EST - Market closed
Utah Medical Products Market Cap
Utah Medical Products has a market cap or net worth of $206.96 million as of December 20, 2024. Its market cap has decreased by -30.46% in one year.
Market Cap
206.96M
Enterprise Value
118.80M
1-Year Change
-30.46%
Ranking
Category
Stock Price
$61.02
Market Cap Chart
Since March 8, 1999, Utah Medical Products's market cap has increased from $49.30M to $206.96M, an increase of 319.79%. That is a compound annual growth rate of 5.72%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Dec 20, 2024 | 207.00M | -32.29% |
Dec 29, 2023 | 305.70M | -16.18% |
Dec 30, 2022 | 364.70M | -0.11% |
Dec 31, 2021 | 365.10M | 18.96% |
Dec 31, 2020 | 306.90M | -23.56% |
Dec 31, 2019 | 401.50M | 29.43% |
Dec 31, 2018 | 310.20M | 2.41% |
Dec 29, 2017 | 302.90M | 10.71% |
Dec 30, 2016 | 273.60M | 24.65% |
Dec 31, 2015 | 219.50M | -2.36% |
Dec 31, 2014 | 224.80M | 5.15% |
Dec 31, 2013 | 213.80M | 60.99% |
Dec 31, 2012 | 132.80M | 35.10% |
Dec 30, 2011 | 98.30M | 1.13% |
Dec 31, 2010 | 97.20M | -8.13% |
Dec 31, 2009 | 105.80M | 25.95% |
Dec 31, 2008 | 84.00M | -27.84% |
Dec 31, 2007 | 116.40M | -10.67% |
Dec 29, 2006 | 130.30M | 5.59% |
Dec 30, 2005 | 123.40M | 33.55% |
Dec 31, 2004 | 92.40M | -23.38% |
Dec 31, 2003 | 120.60M | 28.30% |
Dec 31, 2002 | 94.00M | 37.43% |
Dec 31, 2001 | 68.40M | 81.43% |
Dec 29, 2000 | 37.70M | -13.53% |
View and export this data all the way back to 1999.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Inhibikase Therapeutics | 215.02M |
Zentalis Pharmaceuticals | 213.80M |
Inhibrx Biosciences | 211.35M |
Acrivon Therapeutics | 208.92M |
Lexeo Therapeutics | 207.65M |
Akso Health Group | 204.77M |
Inogen | 201.98M |
Atai Life Sciences | 199.68M |